Cancer Research Meeting Calendar Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oyajobi, B. O.
Right arrow Articles by Mundy, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oyajobi, B. O.
Right arrow Articles by Mundy, G. R.
[Cancer Research 61, 2572-2578, March 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor {kappa}B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy1

Babatunde O. Oyajobi2, Dirk M. Anderson, Kathy Traianedes, Paul J. Williams, Toshiyuki Yoneda and Gregory R. Mundy

Division of Endocrinology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 [B. O. O., K. T., P. J. W., T. Y., G. R. M.], and Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101 [D. M. A.]

Receptor activator of nuclear factor {kappa}B (RANK) is a membrane-bound tumor necrosis factor receptor homologue that mediates signals obligatory for osteoclastogenesis as well as osteoclast activation and survival in vivo. The present study was undertaken to evaluate the efficacy of a soluble murine RANK-human immunoglobulin fusion protein (muRANK.Fc) as a bone resorption inhibitor in vitro and in vivo. The in vitro studies demonstrated the ability of muRANK.Fc to inhibit human parathyroid hormone-related protein (PTHrP)-induced resorption in fetal rat long bone cultures. Short-term administration of muRANK.Fc to normal growing mice resulted in a complete disappearance of osteoclasts from metaphyses of long bones associated with a pronounced increase in calcified trabeculae and bone radiodensity. In a model of humoral hypercalcemia of malignancy in which PTHrP secreted by s.c. xenografts of human lung cancer in nude mice induces extensive osteolysis and severe hypercalcemia, daily administration of muRANK.Fc from time of tumor implantation profoundly inhibited osteoclastic bone resorption and prevented hypercalcemia. muRANK.Fc had no effect on tumor production of PTHrP, because there was no significant difference between circulating human PTHrP levels in muRANK.Fc-treated and vehicle-treated tumor-bearing mice. Moreover, even when treatment was initiated after hypercalcemia was established, muRANK.Fc significantly attenuated further increases in blood ionized calcium. These data demonstrate the potent antiresorptive effects of muRANK.Fc in vivo as well as highlight the potential utility of disrupting RANK signaling as a novel therapeutic approach in humoral hypercalcemia of malignancy and possibly multiple myeloma and skeletal metastases associated with osteolysis.




This article has been cited by other articles:


Home page
 IBMS BoneKEyHome page
M. K. Crook and T. A. Guise
RANKL: Targeting Bone and Cancer to Treat Skeletal Complications of Malignancy
IBMS BoneKEy, September 1, 2009; 6(9): 323 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Sung, A. Murakami, B. O. Oyajobi, and B. B. Aggarwal
Zerumbone Abolishes RANKL-Induced NF-{kappa}B Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice
Cancer Res., February 15, 2009; 69(4): 1477 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Blood, July 1, 2008; 112(1): 196 - 207.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. E. Miller, D. Branstetter, A. Armstrong, B. Kennedy, J. Jones, L. Cowan, J. Bussiere, and W. C. Dougall
Receptor Activator of NF-{kappa}B Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection
J. Immunol., July 1, 2007; 179(1): 266 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Gonzalez-Suarez, D. Branstetter, A. Armstrong, H. Dinh, H. Blumberg, and W. C. Dougall
RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini
Mol. Cell. Biol., February 15, 2007; 27(4): 1442 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Fisher, R. J. Thomas-Mudge, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, T. J. Martin, and M. T. Gillespie
Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Cancer Res., April 1, 2006; 66(7): 3620 - 3628.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H. L. Tan, C. Capparelli, C. Starnes, B. Weimann, et al.
The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy
Endocrinology, August 1, 2005; 146(8): 3235 - 3243.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. L. Olson, L. C. Burkly, D. R. Leone, B. M. Dolinski, and R. R. Lobb
Anti-{alpha}4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model
Mol. Cancer Ther., January 1, 2005; 4(1): 91 - 99.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. C. Hofbauer and M. Schoppet
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
JAMA, July 28, 2004; 292(4): 490 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller
Soluble Receptor Activator of Nuclear Factor {kappa}B Fc Diminishes Prostate Cancer Progression in Bone
Cancer Res., November 15, 2003; 63(22): 7883 - 7890.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. O. Oyajobi, G. Franchin, P. J. Williams, D. Pulkrabek, A. Gupta, S. Munoz, B. Grubbs, M. Zhao, D. Chen, B. Sherry, et al.
Dual effects of macrophage inflammatory protein-1{alpha} on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
Blood, July 1, 2003; 102(1): 311 - 319.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer
RANK ligand and osteoprotegerin in myeloma bone disease
Blood, March 15, 2003; 101(6): 2094 - 2098.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Standal, C. Seidel, O. Hjertner, T. Plesner, R. D. Sanderson, A. Waage, M. Borset, and A. Sundan
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
Blood, September 26, 2002; 100(8): 3002 - 3007.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
M. Ulrich-Vinther, E. E. Carmody, J. J. Goater, K. Søballe, R. J. O'Keefe, and E. M. Schwarz
Recombinant Adeno-Associated Virus-Mediated Osteoprotegerin Gene Therapy Inhibits Wear Debris-Induced Osteolysis
J. Bone Joint Surg. Am., August 12, 2002; 84(8): 1405 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology, January 1, 2002; 2002(1): 214 - 240.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
S. Khosla
Minireview: The OPG/RANKL/RANK System
Endocrinology, December 1, 2001; 142(12): 5050 - 5055.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.